Publications
Showing all 152 journal articles & 33 books available
Journal Articles
1/30/2023
Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS. "A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia." Leukemia.. 2023 Jan 30; Epub 2023 Jan 30.
1/23/2023
Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM. "Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab for Initial Therapy of Chronic Lymphocytic Leukemia." Blood advances.. 2023 Jan 23; Epub 2023 Jan 23.
1/13/2023
Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA. "Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ?5 Years in the RESONATE-2 Study." Cancers.. 2023 Jan 13; 15(2)Epub 2023 Jan 13.
1/9/2023
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Jermain M, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. "Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary." Future oncology.. 2023 Jan 9; Epub 2023 Jan 09.
10/2022
Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA. "CLL-418 Characteristics and Clinical Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Long-Term Ibrutinib Treatment in the RESONATE-2 Study." Clinical lymphoma, myeloma & leukemia.. 2022 Oct; 22 Suppl 2:S278.
8/8/2022
Barr PM, Tedeschi A, Wierda WG, Allan JN, Ghia P, Vallisa D, Jacobs R, O'Brien S, Grigg AP, Walker P, Zhou C, Ninomoto J, Krigsfeld G, Tam CS. "Effective Tumor Debulking With Ibrutinib Before Initiation of Venetoclax: Results From the CAPTIVATE Minimal Residual Disease (MRD) and Fixed-Duration (FD) Cohorts." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2022 Aug 8; Epub 2022 Aug 08.
7/5/2022
Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. "Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 Jul 5; :JCO2102301. Epub 2022 Jul 05.
6/23/2022
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovi? M, Leslie LA, Rhodes J, Chong EA, Kamdar M, Skarbnik AP, Lansigan F, McCall BJ, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo JML, Sail K, Manzoor BS, Furman RR, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park JH, Palomba ML, Zelenetz AD, Eyre TA, Kater AP, Seymour JF, Mato AR. "Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen." Blood advances.. 2022 Jun 23; Epub 2022 Jun 23.
4/15/2022
Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba HP, Stone RM, Litzow MR, Tallman MS, Kay NE. "Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial." Blood.. 2022 Apr 15; Epub 2022 Apr 15.
4/4/2022
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. "Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia." Blood advances.. 2022 Apr 4; Epub 2022 Apr 04.
2/28/2022
Siddiqi T, Coutre S, McKinney M, Barr PM, Rogers K, Mokatrin A, Valentino R, Szoke A, Deshpande S, Zhu A, Arango-Hisijara I, Osei-Bonsu K, Wang M, O'Brien S. "Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma." Leukemia & lymphoma.. 2022 Feb 28; :1-9. Epub 2022 Feb 28.
2/24/2022
Barr PM, Smith S, Roschewski M, O'Brien SM, Sharman JP, Melear JM, Patel P, Calvo R, Yang H, Spurgeon S. "Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma." Leukemia & lymphoma.. 2022 Feb 24; :1-5. Epub 2022 Feb 24.
2/23/2022
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs RW, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson SR, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto JS, Dean JP, Wierda WG, Ghia P. "Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort." Blood.. 2022 Feb 23; Epub 2022 Feb 23.
2/17/2022
Pinney JJ, Blick-Nitko SK, Baran AM, Peterson DR, Whitehead HE, Izumi R, Munugalavadla V, Van DerMeid KR, Barr PM, Zent CS, Elliott MR, Chu CC. "The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact." Haematologica.. 2022 Feb 17; Epub 2022 Feb 17.
8/18/2021
Wang V, Hanson CA, Tschumper R, Lesnick C, Braggio E, Paietta E, O'Brien SM, Barrientos J, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba HP, Stone RM, Litzow MR, Tallman MS, Shanafelt TD, Kay NE. "Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib." Blood.. 2021 Aug 18; Epub 2021 Aug 18.
8/13/2021
Woyach J, Tedeschi A, Munir T, Siddiqi T, Hillmen P, Byrd JC, Ghia P, Mulligan SP, Dai S, Amaya-Chanaga CI, Dean JP, O'Brien SM, Barr PM. "Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma." Leukemia & lymphoma.. 2021 Aug 13; :1-5. Epub 2021 Aug 13.
7/23/2021
Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff A, Davids MS, Baker P, Leslie LA, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, Garcia-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Seddon AN, López-Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu JJ, Patten PE, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik AP, Kamdar M, Jacobs RW, Walter HS, Walewska R, Broom A, Lebowitz S, Isaac K, Portell CA, Ahn IE, Ujjani C, Shadman M, Skånland SS, Chong EA, Mato AR. "COVID-19 in patients with CLL: improved survival outcomes and update on management strategies." Blood.. 2021 Jul 23; Epub 2021 Jul 23.
4/28/2021
Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. "Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 Apr 28; :JCO2100108. Epub 2021 Apr 28.
3/2021
Barr PM. "Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary." Clinical advances in hematology & oncology : H&O.. 2021 Mar; 19 Suppl 11(3):17-19.
12/1/2020
Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, Barrientos J, Rai KR, Reeves JA, Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik AP, Roeker LE, Fonseca G, Sitlinger A, Hamadeh IS, Dorsey C, LaRatta N, Weissbrot H, Luning Prak ET, Tsao PY, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Svoboda J, Brander DM. "Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3K? Inhibitor Therapy." Blood.. 2020 Dec 1; Epub 2020 Dec 01.
10/30/2020
Zent CS, Brady MT, Delage C, Strawderman M, Laniewski N, Contant PN, Kanagaiah P, Sangster MY, Barr PM, Chu CC, Topham DJ, Friedberg JW. "Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma." Leukemia.. 2020 Oct 30; Epub 2020 Oct 30.
10/25/2020
Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM. "Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma." Leukemia & lymphoma.. 2020 Oct 25; :1-8. Epub 2020 Oct 25.
9/24/2020
Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P, . "Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study." Cancer medicine. 2020 Sep 24; Epub 2020 Sep 24.
8/2020
Lipof JJ, Barr PM. "Early Progression of Follicular Lymphoma: Biology and Treatment." Hematology/oncology clinics of North America.. 2020 Aug; 34(4):757-769. Epub 2020 May 05.
7/20/2020
Mato AR, Roeker LE, Lamanna N, Allan J, Leslie LA, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs RW, Ahn IE, Pu JJ, Isaac K, Barr PM, Ujjani C, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hansson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter HS, El-Sharkawi D, Parry H, Wilson MR, Patten PE, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar EB, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. "Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience." Blood.. 2020 Jul 20; Epub 2020 Jul 20.
7/13/2020
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW. "Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 Jul 13; :JCO2000999. Epub 2020 Jul 13.
3/20/2020
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. "Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2020 Mar 20; Epub 2020 Mar 20.
3/16/2020
Meacham PJ, Williams AM, Strawderman M, Baran AM, Archibald WJ, Wallace DS, Tschernia NP, Burack WR, Barr PM, Zent CS. "Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)." Leukemia & lymphoma.. 2020 Mar 16; :1-9. Epub 2020 Mar 16.
3/9/2020
Williams AM, van Wijngaarden E, Seplaki CL, Heckler CE, Weber MT, Barr PM, Zent CS, Janelsins MC. "Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment." Leukemia & lymphoma.. 2020 Mar 9; :1-9. Epub 2020 Mar 09.
3/2020
Godbole MM, Barr PM. "Complete recovery of late onset progressive multifocal leukoencephalopathy related to treatment with chemoimmunotherapy: A case report." Leukemia research.. 2020 Mar; 90:106309. Epub 2020 Jan 21.
2/20/2020
Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, Islam P, Whitaker K, Coombs CC, Tuncer HH, Pagel JM, Jacobs R, Winter AM, Bailey N, Sitlinger A, Schuh AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR. "Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia." Haematologica.. 2020 Feb 20; Epub 2020 Feb 20.
1/17/2020
Moore J, Baran AM, Meacham PJ, Evans AG, Barr PM, Zent CS. "Initial treatment of B-cell prolymphocytic leukemia with ibrutinib." American journal of hematology.. 2020 Jan 17; Epub 2020 Jan 17.
2020
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M. "The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy." Blood and lymphatic cancer : targets and therapy.. 2020 10:1-5. Epub 2020 Aug 24.
12/17/2019
Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM. "Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma." British journal of haematology.. 2019 Dec 17; Epub 2019 Dec 17.
11/13/2019
Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, Tedeschi A, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG. "Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study." Blood.. 2019 Nov 13; 134(Supplement_1):35.
11/4/2019
Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR. "The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia." British journal of haematology.. 2019 Nov 4; Epub 2019 Nov 04.
10/22/2019
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. "Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma." Blood advances.. 2019 Oct 22; 3(20):3132-3135.
10/18/2019
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. "Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study." Leukemia.. 2019 Oct 18; Epub 2019 Oct 18.
10/17/2019
Williams AM, Baran AM, Schaffer M, Bushart J, Rich L, Moore J, Barr PM, Zent CS. "Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy." American journal of hematology.. 2019 Oct 17; Epub 2019 Oct 17.
9/11/2019
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. "Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma." American journal of hematology.. 2019 Sep 11; Epub 2019 Sep 11.
8/14/2019
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. "A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma." Haematologica.. 2019 Aug 14; Epub 2019 Aug 14.
8/9/2019
Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ. "Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 Aug 9; :JCO1901492. Epub 2019 Aug 09.
8/1/2019
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia." The New England journal of medicine.. 2019 Aug 1; 381(5):432-443.
7/25/2019
Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO, Okosun J. "Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs." The oncologist.. 2019 Jul 25; Epub 2019 Jul 25.
7/22/2019
Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW. "." Blood.. 2019 Jul 22; Epub 2019 Jul 22.
7/15/2019
Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. "Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2019 Jul 15; 25(14):4264-4270. Epub 2019 Apr 19.
7/15/2019
Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. "Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia." Clinical lymphoma, myeloma & leukemia.. 2019 Jul 15; Epub 2019 Jul 15.
7/8/2019
Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM. "Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation." Leukemia & lymphoma.. 2019 Jul 8; :1-4. Epub 2019 Jul 08.
7/2019
Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ. "Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States." British journal of haematology.. 2019 Jul; 186(2):255-262. Epub 2019 May 01.
6/25/2019
Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. "Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies." Blood advances.. 2019 Jun 25; 3(12):1799-1807.
5/28/2019
Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. "A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL." Blood advances.. 2019 May 28; 3(10):1568-1573.
5/10/2019
Barr PM. "Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 May 10; 37(14):1151-1153. Epub 2019 Mar 22.
5/9/2019
Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. "Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab." Blood.. 2019 May 9; 133(19):2031-2042. Epub 2019 Mar 06.
3/28/2019
Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. "Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy." Haematologica.. 2019 Mar 28; Epub 2019 Mar 28.
2/14/2019
O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. "Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis." American journal of hematology.. 2019 Feb 14; Epub 2019 Feb 14.
2/10/2019
Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A. "Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies." British journal of haematology.. 2019 Feb 10; Epub 2019 Feb 10.
2/10/2019
Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. "Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia." British journal of haematology.. 2019 Feb 10; Epub 2019 Feb 10.
1/30/2019
Casulo C, Barr PM. "How I treat early relapsing follicular lymphoma." Blood.. 2019 Jan 30; Epub 2019 Jan 30.
12/1/2018
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL." The New England journal of medicine.. 2018 Dec 1; Epub 2018 Dec 01.
11/27/2018
Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M. "Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor." British journal of haematology.. 2018 Nov 27; Epub 2018 Nov 27.
11/2018
Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. "Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies." American journal of hematology.. 2018 Nov; 93(11):1402-1410. Epub 2018 Oct 09.
11/2018
Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. "Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial." American journal of hematology.. 2018 Nov; 93(11):1394-1401. Epub 2018 Sep 26.
10/13/2018
Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM. "Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience." Clinical lymphoma, myeloma & leukemia.. 2018 Oct 13; Epub 2018 Oct 13.
10/2018
O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. "Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2018 Oct; 18(10):648-657.e15. Epub 2018 Jun 28.
10/2018
VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS. "Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies." Cancer immunology research.. 2018 Oct; 6(10):1150-1160. Epub 2018 Aug 08.
9/2018
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. "Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2." Haematologica.. 2018 Sep; 103(9):1502-1510. Epub 2018 Jun 07.
9/2018
Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. "Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States." Haematologica.. 2018 Sep; 103(9):1511-1517. Epub 2018 Jun 07.
8/29/2018
David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM. "Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2018 Aug 29; Epub 2018 Aug 29.
8/22/2018
Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, Kingsley EC, Boyd T, Chen R, Carret AS, Gartner EM, Li H, Yu C, Smith DC. "A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma." Investigational new drugs.. 2018 Aug 22; Epub 2018 Aug 22.
8/15/2018
Barr PM. "Counterpoint: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?" Oncology.. 2018 Aug 15; 32(8):404, 407-9.
8/2018
Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW. "A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806." American journal of hematology.. 2018 Aug; 93(4):486-493. Epub 2018 Jan 25.
8/2018
Archibald WJ, Meacham PJ, Williams AM, Baran AM, Victor AI, Barr PM, Sahasrahbudhe DM, Zent CS. "Management of melanoma in patients with chronic lymphocytic leukemia." Leukemia research.. 2018 Aug; 71:43-46. Epub 2018 Jul 06.
7/19/2018
Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM. "Phase 1 study of the PI3K? inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma." Blood.. 2018 Jul 19; 132(3):293-306. Epub 2018 Apr 25.
6/2018
Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ. "Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma." Haematologica.. 2018 Jun; 103(6):e249-e251. Epub 2017 Nov 23.
5/28/2018
Rodgers TD, Barr PM. "Pitfalls of Combining Novel Agents in Lymphoma." Current treatment options in oncology.. 2018 May 28; 19(7):35. Epub 2018 May 28.
5/2018
Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaack K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS. "Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis." Haematologica.. 2018 May; 103(5):874-879. Epub 2018 Feb 01.
3/2018
Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS. "Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies." Leukemia & lymphoma.. 2018 Mar; 59(3):625-632. Epub 2017 Jul 11.
3/2018
Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW. "R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study." The Lancet. Haematology.. 2018 Mar; 5(3):e102-e108. Epub 2018 Jan 26.
1/2018
Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. "Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL." Leukemia.. 2018 Jan; 32(1):83-91. Epub 2017 Jun 08.
1/2018
Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. "Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial." The Lancet. Oncology.. 2018 Jan; 19(1):65-75. Epub 2017 Dec 12.
10/3/2017
Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL. "Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies." Oncotarget.. 2017 Oct 3; 8(45):79864-79875. Epub 2017 Aug 09.
9/1/2017
Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, Advani R, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J. "Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Sep 1; 28(9):2185-2190.
9/2017
Rowswell-Turner RB, Barr PM. "Treatment of chronic lymphocytic leukemia in older adults." Journal of geriatric oncology.. 2017 Sep; 8(5):315-319. Epub 2017 May 06.
7/2017
Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. "Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib." British journal of haematology.. 2017 Jul; 178(2):286-291. Epub 2017 Apr 10.
6/1/2017
Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW. "Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy." Blood.. 2017 Jun 1; 129(22):3037-3039. Epub 2017 Mar 21.
6/2017
Martin P, Barr PM, James L, Pathak A, Kahl B. "Long-term safety experience with bendamustine for injection in a real-world setting." Expert opinion on drug safety.. 2017 Jun; 16(6):647-650. Epub 2017 Apr 17.
5/11/2017
Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. "Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL." Blood.. 2017 May 11; 129(19):2612-2615. Epub 2017 Apr 03.
5/1/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 1; 28(5):1050-1056.
5/2017
Jaffe ES, Barr PM, Smith SM. "Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice." American Society of Clinical Oncology educational book. 2017 May; (37):535-546.
4/20/2017
Barr PM. "Efficacy in the margins of NHL with ibrutinib." Blood.. 2017 Apr 20; 129(16):2207-2208.
4/2017
Reagan PM, Barr PM. "Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve." The Lancet. Haematology.. 2017 Apr; 4(4):e152-e153. Epub 2017 Mar 15.
3/2017
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. "RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106." British journal of haematology.. 2017 Mar; 176(5):759-769. Epub 2016 Dec 19.
3/2017
Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C. "Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2017 Mar; 17(3):145-151. Epub 2016 Nov 23.
3/2017
Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. "Recommendations for Clinical Trial Development in Follicular Lymphoma." Journal of the National Cancer Institute.. 2017 Mar; 109(3)Epub 2016 Dec 31.
1/27/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jan 27; Epub 2017 Jan 27.
1/25/2017
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. "Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jan 25; Epub 2017 Jan 25.
2017
Jaffe ES, Barr PM, Smith SM. "Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice." American Society of Clinical Oncology educational book. 2017 37:535-546.
12/8/2016
Barr PM. "Deregulation of NF-?B, ie, a useful PMBL marker." Blood.. 2016 Dec 8; 128(23):2591-2592.
11/3/2016
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. "Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience." Blood.. 2016 Nov 3; 128(18):2199-2205. Epub 2016 Sep 06.
11/2016
Reid RM, Baran A, Friedberg JW, Phillips GL, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA. "Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective." Cancer medicine. 2016 Nov; 5(11):3059-3067. Epub 2016 Oct 03.
10/1/2016
Youn P, Cummings MA, Dhakal S, Burack WR, Casulo C, Barr PM, Friedberg JW, Constine LS. "Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy." International journal of radiation oncology, biology, physics.. 2016 Oct 1; 96(2S):E495.
9/15/2016
Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. "Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma." Blood.. 2016 Sep 15; 128(11):1458-64. Epub 2016 Jul 25.
9/2016
Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ. "Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2016 Sep; 16(9):e123-e127. Epub 2016 Jun 08.
8/25/2016
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O. "Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy." Blood.. 2016 Aug 25; 128(8):1112-20. Epub 2016 Jul 14.
7/2016
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. "Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia." Haematologica.. 2016 Jul; 101(7):e295-8. Epub 2016 May 05.
6/10/2016
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. "US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 Jun 10; 34(17):2020-7. Epub 2016 Apr 11.
6/2016
Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW. "Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2016 Jun; 16(6):322-328.e2. Epub 2016 Apr 02.
5/19/2016
Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW. "Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL." Blood.. 2016 May 19; 127(20):2411-5. Epub 2016 Mar 11.
3/24/2016
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. "Postibrutinib outcomes in patients with mantle cell lymphoma." Blood.. 2016 Mar 24; 127(12):1559-63. Epub 2016 Jan 13.
2016
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. "Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas." Leukemia & lymphoma.. 2016 57(3):635-43. Epub 2015 Oct 12.
12/17/2015
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, . "Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia." The New England journal of medicine.. 2015 Dec 17; 373(25):2425-37. Epub 2015 Dec 06.
12/2015
Choudary I, Barr PM, Friedberg J. "Recent advances in the development of Aurora kinases inhibitors in hematological malignancies." Therapeutic advances in hematology.. 2015 Dec; 6(6):282-94.
8/2015
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma." Nature medicine.. 2015 Aug; 21(8):922-6. Epub 2015 Jul 20.
7/20/2015
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. "Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 Jul 20; 33(21):2399-404. Epub 2015 Jun 15.
5/7/2015
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. "The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia." Blood.. 2015 May 7; 125(19):2915-22. Epub 2015 Mar 09.
3/2015
Barr PM. "Rituximab maintenance in follicular lymphoma." Clinical advances in hematology & oncology : H&O.. 2015 Mar; 13(3):158-61.
2/2015
Hutchinson K, Jahangiri S, Calvi LM, Barr P, Friedberg JW, Kelly JL. "Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma." Leukemia & lymphoma.. 2015 Feb; 56(2):508-11. Epub 2014 Jul 15.
12/2014
Barr PM, Zent CS. "Infection in chronic lymphocytic leukemia: parsimony has its limits." Leukemia & lymphoma.. 2014 Dec; 55(12):2683-4. Epub 2014 May 16.
9/2014
Jahangiri S, Barr P, Friedberg J. "Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma." Expert opinion on emerging drugs.. 2014 Sep; 19(3):367-83. Epub 2014 Jun 24.
8/21/2014
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. "Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma." Blood.. 2014 Aug 21; 124(8):1259-65. Epub 2014 Jul 11.
8/2014
Barr PM. "Maintenance rituximab should be considered for patients with follicular lymphoma." Clinical advances in hematology & oncology : H&O.. 2014 Aug; 12(8):541-3.
7/17/2014
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, . "Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia." The New England journal of medicine.. 2014 Jul 17; 371(3):213-23. Epub 2014 May 31.
7/2014
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jul; 25(7):1449.
7/2014
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"." Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jul; 25(7):1449. Epub 2019 Dec 04.
6/20/2014
Brown JR, O'Brien SM, Barrientos JC, Kay NE, Reddy NM, Coutre SE, Tam C, Mulligan SP, Jäger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Fardis M, McGreivy JS, Clow F, James DF, Hillmen P. "Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 Jun 20; 32(18_suppl):LBA7008.
6/2014
Barr PM, Zent CS. "The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management." Leukemia & lymphoma.. 2014 Jun; 55(6):1219-20. Epub 2013 Nov 01.
3/1/2014
Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P. "Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma." Journal of the National Comprehensive Cancer Network : JNCCN.. 2014 Mar 1; 12(3):323-6; quiz 326.
12/2013
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI. "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma." Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Dec; 24(12):3076-81. Epub 2013 Oct 20.
10/2013
Barr PM. "Flavopiridol: Judged by the company one keeps." Leukemia research.. 2013 Oct; 37(10):1187-8. Epub 2013 Jul 08.
8/2013
Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. "Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia." Leukemia.. 2013 Aug; 27(8):1769-73. Epub 2013 Feb 06.
2/2013
Barr PM. "Fffuse large B-cell lymphoma in the very elderly: the case for refining our clinical trials." Oncology.. 2013 Feb; 27(2):140, 142.
12/2012
Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore P, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A. "Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium." Leukemia & lymphoma.. 2012 Dec; 53(12):2383-9. Epub 2012 Jul 09.
7/2012
Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ, Carlson-Barko JM, Laughlin MJ. "Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies." Bone marrow transplantation.. 2012 Jul; 47(7):924-33. Epub 2011 Oct 17.
6/2012
Noel MS, Friedberg JW, Barr PM. "Novel agents in mantle cell lymphoma." Best practice & research. Clinical haematology.. 2012 Jun; 25(2):191-200. Epub 2012 Apr 30.
3/2012
Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW. "Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion." Clinical immunology : the official journal of the Clinical Immunology Society.. 2012 Mar; 142(3):237-42. Epub 2012 Jan 05.
2012
Caimi PF, Barr PM, Berger NA, Lazarus HM. "Non-Hodgkin's Lymphoma in the Elderly". Drugs & Aging. 2012; 27(3): 211-238.
2012
Noel, MS; Friedberg, JW; Barr, PM;. "Novel agents in mantle cell lymphoma". Best Practices & Resaerch Clinical Haematology. 2012; 25(2): 191-200.
11/2011
Carter SJ, Bernstein SH, Friedberg JW, Barr PM. "Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma." Leukemia research.. 2011 Nov; 35(11):e223-4. Epub 2011 Aug 06.
7/2011
Lazarus HM, Sommers SR, Arfons LM, Fu P, Ataergin SA, Kaye NM, Liu F, Kindwall-Keller TL, Cooper BW, Laughlin MJ, Creger RJ, Barr PM, Gerson SL, Kaplan D. "Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2011 Jul; 17(7):970-8. Epub 2011 Apr 11.
7/2011
Barr PM, Friedberg JW. "Getting to the heart of the problem in treating diffuse large B-cell lymphoma." Leukemia & lymphoma.. 2011 Jul; 52(7):1166-7. Epub 2011 May 25.
6/2011
Dao H, Barr PM, Honda K. "Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox." Journal of the American Academy of Dermatology.. 2011 Jun; 64(6):e123-5.
9/2010
Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. "Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia." Cell death and differentiation.. 2010 Sep; 17(9):1381-91. Epub 2010 Mar 19.
3/1/2010
Caimi PF, Barr PM, Berger NA, Lazarus HM. "Non-Hodgkin's lymphoma in the elderly." Drugs & aging.. 2010 Mar 1; 27(3):211-38.
3/2010
Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM. "Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL." Cytometry. Part B, Clinical cytometry.. 2010 Mar; 78(2):115-22.
10/2009
Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW. "Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma." British journal of haematology.. 2009 Oct; 147(1):89-96. Epub 2009 Jun 29.
8/2009
Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC. "Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant." American journal of hematology.. 2009 Aug; 84(8):484-7.
6/2009
Rong YP, Barr P, Yee VC, Distelhorst CW. "Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor." Biochimica et biophysica acta.. 2009 Jun; 1793(6):971-8. Epub 2008 Nov 12.
9/2008
Barr PM, Lazarus HM. "Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation." Current opinion in oncology.. 2008 Sep; 20(5):502-8.
12/2007
Barr P, Fisher R, Friedberg J. "The role of bortezomib in the treatment of lymphoma." Cancer investigation.. 2007 Dec; 25(8):766-75.
10/2007
Barr P, Fu P, Lazarus H, Kane D, Meyerson H, Hartman P, Reyes R, Creger R, Stear K, Laughlin M, Tse W, Cooper B. "Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia." Leukemia & lymphoma.. 2007 Oct; 48(10):1940-9.
7/18/1997
Malinowski MN, Cannady SB, Schmit KV, Barr PM, Schrock JW, Wilson DF. "Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat." Neuroscience letters.. 1997 Jul 18; 230(2):81-4.
Barr PM, Zent CS. "The ABC of chronic lymphocytic leukemia: Etiology of cytopenias is important in staging and management". Leukemia Lymphoma [EPub in press].